Literature DB >> 11839844

A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial.

J Quinn1, M Moore, D F Benson, C M Clark, R Doody, W Jagust, D Knopman, J A Kaye.   

Abstract

BACKGROUND: The global impression of a clinician is an Food and Drug Administration--mandated primary outcome measure for clinical trials in dementia. Reliability and validity of these measures are not well established.
METHODS: A videotaped version of the Clinician's Interview Based Impression of Change (CIBIC) was evaluated. Raters were informed that the videotaped interviews were taken at baseline and 6 to 12 months later, when in fact half of the interviews were shown in reverse order. Ratings on "true order" interviews were compared with ratings on "reverse order" interviews. In addition, ratings by neurologists experienced in dementia were compared with those of less experienced raters.
RESULTS: Inter-rater reliability of the neurologists was poor when measured by absolute agreement on a 7-point scale (kappa = 0.18). With a less stringent 3-point scale (better, worse, or unchanged), inter-rater reliability was significantly better for the true order videos (kappa = 0.51) than for the reversed order videos (kappa = 0.12). Validity also was reduced in the reverse order group: neurologists rated 90% of subjects correctly in the "true order" group and 63% correctly in the "reversed order" group. The inter-rater reliability of the neurologists was greater than the less experienced raters, but the validity of the neurologists' ratings was only marginally better.
CONCLUSIONS: The reliability and validity of the videotape CIBIC are reasonable when patients follow the expected course of gradual decline, but are poor when patients appear to improve. These findings suggest that global assessments should be modified as outcome measures in clinical trials with patients with dementia.

Entities:  

Mesh:

Year:  2002        PMID: 11839844     DOI: 10.1212/wnl.58.3.433

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.

Authors:  K Rockwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders Using Internet-Based Technologies.

Authors:  Kenneth A Kobak; Kate Wolitzky-Taylor; Michelle G Craske; Raphael D Rose
Journal:  Cognit Ther Res       Date:  2016-11-15

3.  Web-based therapist training on cognitive behavior therapy for anxiety disorders: a pilot study.

Authors:  Kenneth A Kobak; Michelle G Craske; Raphael D Rose; Kate Wolitsky-Taylor
Journal:  Psychotherapy (Chic)       Date:  2013-02-11

4.  Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.

Authors:  Taim Muayqil; Richard Camicioli
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-11-23

5.  A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.

Authors:  T Fields; M Patterson; T Bremova-Ertl; G Belcher; I Billington; G C Churchill; W Davis; W Evans; S Flint; A Galione; U Granzer; J Greenfield; R Karl; R Kay; D Lewi; T Mathieson; T Meyer; D Pangonis; F M Platt; L Tsang; C Verburg; M Factor; M Strupp
Journal:  Trials       Date:  2021-01-22       Impact factor: 2.279

6.  Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1.

Authors:  Christopher Carswell; Michael Rañopa; Suvankar Pal; Rebecca Macfarlane; Durre Siddique; Dafydd Thomas; Tom Webb; Steve Wroe; Sarah Walker; Janet Darbyshire; John Collinge; Simon Mead; Peter Rudge
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-08-08

7.  The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.

Authors:  Kenneth Rockwood; Sherri Fay; Mary Gorman; Daniel Carver; Janice E Graham
Journal:  BMC Neurol       Date:  2007-08-30       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.